<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167700</url>
  </required_header>
  <id_info>
    <org_study_id>15214</org_study_id>
    <nct_id>NCT00167700</nct_id>
  </id_info>
  <brief_title>Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight</brief_title>
  <acronym>NAMI</acronym>
  <official_title>Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI)
      was created with the objective to reverse the rising trend of chronic inflammatory diseases,
      such as allergic disease and obesity, by control of the internal and external environments of
      the infant. To approach this problem, the project aims to characterize

        -  how immunology is regulated during pregnancy and early infancy,

        -  how the immune interaction between mother and child is influenced by nutritional and
           microbial factors, and

        -  how the regulation is related to disease risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While allergic diseases comprise the most common chronic disease in childhood, obesity is the
      most prevalent nutritional disorder among children throughout the world. In Europe, an
      estimated 20% of children and adolescents are overweight with one-third of these being
      considered obese. Moreover, escalation of these problems is expected in the future, since the
      velocity of propagation is highest in children. Although genetic factors can determine the
      propensity of an individual to become allergic or obese, these unlikely explain the recent
      and progressive worldwide increases in incidence. Rather, it would appear that the
      environmental changes more directly shape the risk during a critical period of life when the
      scene is set for the consolidation of the immune responder type. Prenatal environmental
      exposures may alter gene expression via epigenetic mechanisms, heritable changes in gene
      expression occurring without alterations in the DNA sequences.

      Specifically current research interest is directed towards health promotion and reducing the
      risk of disease evaluating the probiotic effects with specific foods and nutrients, and
      assessing their interactions in optimal combination and food matrix. For this purpose a
      series of interventions studies evaluate the both the optimal timing of probiotic
      intervention and the optimal mode of administration.

      Sections:

      Prenatal

      RCT 2 Randomized, parallel-design clinical trial of 3 groups. Pregnant women (n=256) from
      families with at least one member having an allergic disease have been recruited from
      maternal welfare clinics and randomly assigned to control group or one of the intervention
      groups. Mothers in the dietary intervention groups received dietary counselling with specific
      attention to the quality and quantity of fat in the diet. To promote the achievement of
      current dietary recommendations, mothers have been provided with foods which have a
      favourable fat composition (e.g. spreads). The subjects in the intervention groups have been
      further randomized (double-blind randomization) to receive either placebo or a probiotic
      preparation, 1010 cfu of both Lactobacillus rhamnosus GG and Bifidobacterium lactis and
      controls received placebo in a single-blind manner. Dietary food products and probiotic
      supplementation have been continued from the 1st trimester of pregnancy until the end of
      exclusive breast feeding, maximum of 6 months.

      Perinatal

      RCT 1 Randomized double-blind, placebo-controlled study of 2 groups. Pregnant women (n=159)
      have been randomized into one of the study groups 2-4 weeks before term to receive placebo
      (microcrystalline cellulose) or probiotic Lactobacillus rhamnosus GG (ATCC 53103; 1010 cfu).
      After delivery probiotics/ placebo were administered orally to the infants for 6 months.
      General information to prevent allergy has been given in written form to all: to breast-feed
      for at least 4-6 months; to begin solid foods at 4-6 months; no smoking by caretakers.

      RCT 3 Randomized double-blind, placebo-controlled clinical trial of 3 groups. Pregnant women
      (n=241) with a history of atopic diseases have been assigned to one of the treatment groups:
      to receive for 2 months before delivery and for 2 months thereafter, when they are
      breast-feeding, either placebo or Lactobacillus rhamnosus and Bifidobacterium longum or
      Lactobacillus paracasei and Bifidobacterium longum.

      Postnatal

      RCT 4 Randomized double-blind, placebo-controlled study of 3 groups. Neonates (n=94)
      fulfilling the following criteria: gestational age at birth between 32nd and 36th weeks,
      weight over 1500 g and no congenital defects of gastrointestinal system or other defects that
      prevent enteral nutrition, have been randomized to receive either placebo (microcrystalline
      cellulose) or a probiotic preparation (Lactobacillus rhamnosus GG, ATCC 53103) or a prebiotic
      preparation (a mixture of Polydextrose and Galacto-oligosaccharideOS in a 1:1 ratio). The
      treatment continues for 2 months.

      RCT 5 Randomized double-blind, placebo-controlled clinical trial of 2 groups. 2-6 weeks old
      formula- and breast-fed colic infants (n=30), who cry without medical cause for 3h/d, for
      3days/week, have been randomized to receive either placebo (microcrystalline cellulose) or a
      probiotic preparation (Lactobacillus rhamnosus GG, ATCC 53103) for 4 weeks. Formula-fed
      infants receive extensively hydrolysed formula and mothers of breast-fed infants avoid cow's
      milk in their diet.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 1997</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with allergic disease</measure>
    <time_frame>Up to 13 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight gain</measure>
    <time_frame>Up to 13 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with chronic inflammatory disease</measure>
    <time_frame>Up to 13 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Innate immune gene expression patterns</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition</measure>
    <description>Amount of bacterial cells (per gram of faeces of mothers and infants as well as of breast milk) is measured using multiple methods, i.e. pyrosequencing, HIT-CHIP, qPCR, FISH and DGGE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in peripheral blood</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile in breast milk</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile in peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GHbA1c</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acids</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoproteins</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intakes of foods and nutrients</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukotrienes in peripheral blood</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokines</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of crying in minutes</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Crying minutes per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with functional gastrointestinal disorders</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral infections</measure>
    <time_frame>Up to 13 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Allergic Disease</condition>
  <condition>Obesity</condition>
  <condition>Immunology</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics + Dietary counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietary counseling + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary counselling and placebo</intervention_name>
    <description>Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.</description>
    <arm_group_label>Dietary counseling + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dietary counselling and probiotics</intervention_name>
    <description>Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics</description>
    <arm_group_label>Probiotics + Dietary counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotics</intervention_name>
    <arm_group_label>Prebiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women from families with at least one family member having an allergic
             disease

        Exclusion Criteria:

          -  Women presenting severe immunological or other chronic diseases (rheumatoid arthritis,
             diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)

          -  Women who cannot be expected to comply with treatment

          -  Women currently participating or having participated in other clinical trial during
             the last 2 months prior to the beginning of the intervention.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika Isolauri, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Hvitfelt-Koskelainen, RN</last_name>
    <phone>+358 2 313 0000</phone>
    <phone_ext>1463</phone_ext>
    <email>Johanna.Hvitfelt-Koskelainen@tyks.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Isolauri, MD, PhD</last_name>
      <phone>+358 2 313 0000</phone>
      <phone_ext>2433</phone_ext>
      <email>erika.isolauri@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Erika Isolauri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seppo Salminen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsi Laitinen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marko Kalliomäki, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuli Rautava, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minna-Maija Grönlund, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merja Nermes, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Carmen Collado, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulla Hoppu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raakel Luoto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonna Normia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://fff.utu.fi/tutkimus/nami/</url>
    <description>The home page of the research group (only partly in English)</description>
  </link>
  <results_reference>
    <citation>Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9.</citation>
    <PMID>11297958</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1869-71.</citation>
    <PMID>12788576</PMID>
  </results_reference>
  <results_reference>
    <citation>Laiho K, Lampi AM, Hamalainen M, Moilanen E, Piironen V, Arvola T, Syrjanen S, Isolauri E. Breast milk fatty acids, eicosanoids, and cytokines in mothers with and without allergic disease. Pediatr Res. 2003 Apr;53(4):642-7. Epub 2003 Jan 29.</citation>
    <PMID>12612204</PMID>
  </results_reference>
  <results_reference>
    <citation>Laitinen K, Kalliomäki M, Poussa T, Lagström H, Isolauri E. Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years. Br J Nutr. 2005 Oct;94(4):565-74.</citation>
    <PMID>16197582</PMID>
  </results_reference>
  <results_reference>
    <citation>Collado MC, Laitinen K, Salminen S, Isolauri E. Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. Pediatr Res. 2012 Jul;72(1):77-85. doi: 10.1038/pr.2012.42. Epub 2012 Mar 27.</citation>
    <PMID>22453296</PMID>
  </results_reference>
  <results_reference>
    <citation>Laitinen K, Poussa T, Isolauri E; Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr. 2009 Jun;101(11):1679-87. doi: 10.1017/S0007114508111461. Epub 2008 Nov 19.</citation>
    <PMID>19017418</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoppu U, Isolauri E, Laakso P, Matomäki J, Laitinen K. Probiotics and dietary counselling targeting maternal dietary fat intake modifies breast milk fatty acids and cytokines. Eur J Nutr. 2012 Mar;51(2):211-9. doi: 10.1007/s00394-011-0209-0. Epub 2011 May 31.</citation>
    <PMID>21626296</PMID>
  </results_reference>
  <results_reference>
    <citation>Niinivirta K, Isolauri E, Laakso P, Linderborg K, Laitinen K. Dietary counseling to improve fat quality during pregnancy alters maternal fat intake and infant essential fatty acid status. J Nutr. 2011 Jul;141(7):1281-5. doi: 10.3945/jn.110.137083. Epub 2011 May 18.</citation>
    <PMID>21593355</PMID>
  </results_reference>
  <results_reference>
    <citation>Ilmonen J, Isolauri E, Poussa T, Laitinen K. Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clin Nutr. 2011 Apr;30(2):156-64. doi: 10.1016/j.clnu.2010.09.009.</citation>
    <PMID>20970896</PMID>
  </results_reference>
  <results_reference>
    <citation>Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counseling during pregnancy on colostrum adiponectin concentration: a prospective, randomized, placebo-controlled study. Early Hum Dev. 2012 Jun;88(6):339-44. doi: 10.1016/j.earlhumdev.2011.09.006. Epub 2011 Sep 25.</citation>
    <PMID>21945174</PMID>
  </results_reference>
  <results_reference>
    <citation>Ojala T, Aaltonen J, Siira S, Jalonen J, Ekholm E, Ekblad U, Laitinen K. Fetal cardiac sympathetic activation is linked with maternal body mass index. Early Hum Dev. 2009 Sep;85(9):557-60. doi: 10.1016/j.earlhumdev.2009.05.009. Epub 2009 Jun 12.</citation>
    <PMID>19524376</PMID>
  </results_reference>
  <results_reference>
    <citation>Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr. 2010 Jun;103(12):1792-9. doi: 10.1017/S0007114509993898. Epub 2010 Feb 4.</citation>
    <PMID>20128938</PMID>
  </results_reference>
  <results_reference>
    <citation>Collado MC, Isolauri E, Laitinen K, Salminen S. Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. Am J Clin Nutr. 2010 Nov;92(5):1023-30. doi: 10.3945/ajcn.2010.29877. Epub 2010 Sep 15.</citation>
    <PMID>20844065</PMID>
  </results_reference>
  <results_reference>
    <citation>Aaltonen J, Ojala T, Laitinen K, Poussa T, Ozanne S, Isolauri E. Impact of maternal diet during pregnancy and breastfeeding on infant metabolic programming: a prospective randomized controlled study. Eur J Clin Nutr. 2011 Jan;65(1):10-9. doi: 10.1038/ejcn.2010.225. Epub 2010 Oct 13.</citation>
    <PMID>20948557</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <keyword>atopic disease</keyword>
  <keyword>probiotics</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>allergy</keyword>
  <keyword>nutrition</keyword>
  <keyword>growth</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>atopic sensitization</keyword>
  <keyword>risk-markers of life-style related diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

